Sonoma Bio to cement its roots in Seattle with a new waterfront manufacturing and R&D site
A year after Jeff Bluestone’s Sonoma Biotherapeutics netted $265 million in a huge Series B, the biotech is now looking to establish itself in the manufacturing ecosystem of the Pacific Northwest.
Sonoma has entered into a lease agreement to develop an 83,000-square-foot manufacturing and R&D center in Seattle, the company said Wednesday. The company’s gene modified Treg therapies, born out of the R&D lab in South San Francisco, will be made at the site.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.